Maplight Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 7.4% of MapLight Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
Forbion Growth Opportunities Fund III Cooperatief U.A. and Forbion Growth III Management B.V. have disclosed a 7.1% beneficial ownership stake in MapLight Therapeutics, Inc.